NO20092496L - Ny terapeutisk anvendelse for behandling av leukemi - Google Patents

Ny terapeutisk anvendelse for behandling av leukemi

Info

Publication number
NO20092496L
NO20092496L NO20092496A NO20092496A NO20092496L NO 20092496 L NO20092496 L NO 20092496L NO 20092496 A NO20092496 A NO 20092496A NO 20092496 A NO20092496 A NO 20092496A NO 20092496 L NO20092496 L NO 20092496L
Authority
NO
Norway
Prior art keywords
leukemia
treatment
new therapeutic
therapeutic application
new
Prior art date
Application number
NO20092496A
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38268928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092496(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20092496L publication Critical patent/NO20092496L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er beskrevet en ny terapeutisk anvendelse for behandling, av leukemi spesielt myeolid leukemi.
NO20092496A 2006-12-28 2009-07-02 Ny terapeutisk anvendelse for behandling av leukemi NO20092496L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611492A FR2910813B1 (fr) 2006-12-28 2006-12-28 Nouvelle utilisation therapeutique pour le traitement des leucemies
PCT/FR2007/002171 WO2008102075A2 (fr) 2006-12-28 2007-12-27 Nouvelle utilisation therapeutique pour le traitement des leucemies

Publications (1)

Publication Number Publication Date
NO20092496L true NO20092496L (no) 2009-07-23

Family

ID=38268928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092496A NO20092496L (no) 2006-12-28 2009-07-02 Ny terapeutisk anvendelse for behandling av leukemi

Country Status (39)

Country Link
US (1) US8236811B2 (no)
EP (1) EP2107906B1 (no)
JP (1) JP5317987B2 (no)
KR (1) KR101458233B1 (no)
CN (1) CN101568338B (no)
AR (1) AR064550A1 (no)
AT (1) ATE534392T1 (no)
AU (1) AU2007347370B2 (no)
BR (1) BRPI0720963A2 (no)
CA (1) CA2672716C (no)
CL (1) CL2007003846A1 (no)
CO (1) CO6190610A2 (no)
CR (1) CR10881A (no)
CY (1) CY1112443T1 (no)
DK (1) DK2107906T3 (no)
EA (1) EA016873B1 (no)
EC (1) ECSP099449A (no)
ES (1) ES2377843T3 (no)
FR (1) FR2910813B1 (no)
GT (1) GT200900168A (no)
HR (1) HRP20120170T1 (no)
JO (1) JO2748B1 (no)
MA (1) MA31100B1 (no)
MX (1) MX2009007054A (no)
MY (1) MY148515A (no)
NI (1) NI200900129A (no)
NO (1) NO20092496L (no)
NZ (1) NZ577991A (no)
PE (1) PE20081548A1 (no)
PL (1) PL2107906T3 (no)
PT (1) PT2107906E (no)
RS (1) RS52162B (no)
SI (1) SI2107906T1 (no)
SV (1) SV2009003315A (no)
TN (1) TN2009000234A1 (no)
TW (1) TWI433678B (no)
UA (1) UA97505C2 (no)
WO (1) WO2008102075A2 (no)
ZA (1) ZA200904478B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
EP2638911A1 (en) * 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
MY194303A (en) * 2013-12-13 2022-11-27 Novartis Ag Pharmaceutical dosage forms
US20230136218A1 (en) * 2019-09-23 2023-05-04 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
FI971953A7 (fi) 1994-11-14 1997-05-12 Warner Lambert Co Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
WO2001055147A1 (en) * 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
JP2004519422A (ja) 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Also Published As

Publication number Publication date
TWI433678B (zh) 2014-04-11
DK2107906T3 (da) 2012-03-19
HRP20120170T1 (hr) 2012-03-31
CY1112443T1 (el) 2015-12-09
ATE534392T1 (de) 2011-12-15
EP2107906A2 (fr) 2009-10-14
MY148515A (en) 2013-04-30
HK1138189A1 (en) 2010-08-20
UA97505C2 (ru) 2012-02-27
CO6190610A2 (es) 2010-08-19
US8236811B2 (en) 2012-08-07
JP5317987B2 (ja) 2013-10-16
NZ577991A (en) 2012-01-12
AU2007347370B2 (en) 2013-05-23
PT2107906E (pt) 2012-03-05
EA016873B1 (ru) 2012-08-30
ECSP099449A (es) 2009-07-31
ES2377843T3 (es) 2012-04-02
FR2910813B1 (fr) 2009-02-06
CN101568338B (zh) 2011-11-23
EP2107906B1 (fr) 2011-11-23
MX2009007054A (es) 2009-08-12
WO2008102075A3 (fr) 2008-12-11
CN101568338A (zh) 2009-10-28
ZA200904478B (en) 2010-08-25
PE20081548A1 (es) 2009-01-04
CA2672716C (fr) 2013-05-28
US20090298790A1 (en) 2009-12-03
PL2107906T3 (pl) 2012-04-30
KR20090103899A (ko) 2009-10-01
MA31100B1 (fr) 2010-01-04
EA200970639A1 (ru) 2010-04-30
FR2910813A1 (fr) 2008-07-04
NI200900129A (es) 2011-12-13
JP2010514743A (ja) 2010-05-06
CA2672716A1 (fr) 2008-08-28
JO2748B1 (en) 2014-03-15
TN2009000234A1 (fr) 2010-10-18
AR064550A1 (es) 2009-04-08
CL2007003846A1 (es) 2009-01-23
GT200900168A (es) 2010-03-19
AU2007347370A1 (en) 2008-08-28
TW200833343A (en) 2008-08-16
BRPI0720963A2 (pt) 2014-03-18
RS52162B (sr) 2012-08-31
SI2107906T1 (sl) 2012-03-30
SV2009003315A (es) 2010-02-05
WO2008102075A2 (fr) 2008-08-28
CR10881A (es) 2009-08-12
KR101458233B1 (ko) 2014-11-04

Similar Documents

Publication Publication Date Title
LTPA2020536I1 (lt) Nauji anti-CD38 antikūnai, skirti vėžio gydymui
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
BRPI0718146A2 (pt) Dispositivos de infusão e métodos
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
DE502007002639D1 (de) Plasmabrennerkopf, plasmabrennerschaft und plasmabrenner
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
CR10157A (es) Compuestos químicos
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20082413L (no) Mikrobiocidal sammensetning
EA200802111A1 (ru) Имплантаты для лечения состояний, ассоциируемых с допамином
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
EA201000258A1 (ru) Новые гербициды
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
EA201000069A1 (ru) Новые гербициды
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
MY148651A (en) Antitumoral compounds
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
MX2010001303A (es) Compuestos terapeuticos.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
CY1112443T1 (el) Νεα θεραπευτικη χρηση για τη θεραπεια των λευχαιμιων

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application